TGFB1 and Parkinson disease: As a result, the local delivery of the ALK-5 receptor using an AAV vector (AAV-ALK-5) significantly reduced dopaminergic neurodegeneration, as well as motor deficits, suggesting the potential of TGF-β1 in PD therapy.